Inclusion criteria relating to the study design were not reported. Studies with fewer than 10 patients were excluded.
Results of the review
Twelve studies were eligible for inclusion. Four were randomised controlled trials (RCTs), while eight used an observational design.
Two studies met the minimal criteria for validity.
Three RCTs studied the efficacy of different doses of BTX-A. Treatment with BTX-A resulted in tone reduction and improvements in passive range of motion (PROM) in comparison with placebo. However, a clear improvement in functional abilities was not demonstrated in any of the included studies. The findings of the observational studies that investigated BTX-A supported those of the RCTs.
One RCT investigated the efficacy of combining BTX-A with electrical stimulation (ES). The study found evidence of a synergistic effect of the combined treatment. In particular, treatment with BTX-A and ES seemed superior with regard to hand hygiene and spasticity reduction.
A clear dose-response relationship was not demonstrated in any of the RCTs, but the authors noted that there was a tendency for a dose-related improvement in the Ashworth score and PROM.
Only minor side-effects were reported in the included studies. These included transient skin rash, soreness and pain at the injection site.
Two observational studies (neither of which included a control group) investigated the effectiveness of alcohol neurolysis and phenol neuromuscular blockade, respectively. Significant improvements in tone and PROM were found in patients treated with alcohol neurolysis, and the effects were shown to last for up to 6 months. Improvements in PROM were seen in patients treated with phenol. However, an adequate measure of shoulder pain was not reported. The most common side-effect reported in both studies was a transient soreness over the injection site.
